Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
The market approval for Fayuvi, which was rejected in 2025 due to manufacturing problems, comes shortly after Ultragenyx got the FDA nod for its first gene therapy last month.
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M Read More »
